European Radiology:超声弹性成像在预测乳腺癌新辅助化疗后腋窝淋巴结状态中的应用

2022-08-23 shaosai MedSci原创

与传统的US相比,超声弹性成像(UE)可以提供有关组织硬度的额外信息,这与肿瘤的发生和疾病的发展关系密切。

现阶段新辅助化疗(NAC)后进行手术治疗是局部晚期乳腺癌和淋巴结阳性患者的标准治疗手段。根据目前的指南,腋窝淋巴结清扫术(ALND)适用于在NAC之前有病理证实的淋巴结受累患者。然而,ALND可能导致如手臂疼痛、淋巴水肿和手臂活动受限术后并发症

因此,随着NAC效用的增加和化疗疗效的提高,对于NAC后转为淋巴结阴性的乳腺癌患者,ALND术式的使用受到了临床上的广泛质疑。对于这些患者,如前哨淋巴结活检(SLNB)有针对性的腋窝清扫是现阶段普遍公认的ALND替代方法。

尽管越来越多的证据支持在最初淋巴结阳性的乳腺癌患者中进行SLNB的可行性,但假阴性率(FNRs)通常高得令人无法接受。

与传统的US相比,超声弹性成像(UE)可以提供有关组织硬度的额外信息,这与肿瘤的发生和疾病的发展关系密切。超声弹性成像包括应变弹性成像(SE)和剪切波弹性成像(SWE),其中SWE在评估乳腺病变的硬度方面更具有可重复性和定量性的优势。然而,据我们所知,已发表的研究SWE预测NAC后腋窝LN状态的文献并不多见。

近日,发表在European Radiology杂志的一项研究探讨了结合腋窝US和乳腺SWE在检测最初经活检证实的淋巴结阳性乳腺癌患者NAC后残留的腋窝LN转移的价值,为临床早期、准确且无创的评估乳腺癌患者的腋窝淋巴结状态提供了技术支持。

本研究于2016年9月-2021年12月期间对接受NAC的201名淋巴结阳性乳腺癌患者进行了评估。分析了NAC后腋窝淋巴结的常规US特征和乳腺病灶的SWE特征。使用多变量逻辑回归和ROC分析评估了US、SWE及其组合的诊断性能。 

传统的US特征判断NAC后腋窝状态的能力的ROC曲线下面积(AUC)为0.82,敏感性为85.23%,特异性为67.39%,准确性为76.11%。剪切波速度(SWV)在预测NAC后的腋窝状态方面显示出中等的性能,SWVmean显示出AUC为0.85。腋窝淋巴结的皮质厚度和形状以及乳腺肿瘤的SWVmean与NAC后的腋窝结节转移有独立关联。与传统的US相比,腋窝淋巴结的传统US与乳腺病变的SWE相结合,取得了明显更高的AUC(0.90 vs 0.82,P < 0.01,Delong检验),敏感性为87.50%,特异性提高到82.61%,准确性为85.00%。 


图 剪切波弹性成像(SWE)对乳腺病变的显示。A 乳腺癌病灶的超声灰度图像。B 定量SWE的质量图。C 定量SWE的速度图。最大和最小的剪切波速度值分别在成像质量高的最硬和最软的区域(质量图上的绿色区域)获得

本研究结果表明,乳腺SWE可以作为用于评估NAC后腋窝淋巴结状态的补充成像手段。与单独的常规超声相比,常规超声与SWE的组合显示出更高的诊断性能,是确定淋巴结状态的一种十分有临床前景的手段,使得接受NAC的患者进行更少的侵入性治疗。

 

原文出处:

Jia-Xin Huang,Shi-Yang Lin,Yan Ou,et al.Combining conventional ultrasound and sonoelastography to predict axillary status after neoadjuvant chemotherapy for breast cancer.DOI:10.1007/s00330-022-08751-1

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1931877, encodeId=618c19318e775, content=<a href='/topic/show?id=7a6b8532324' target=_blank style='color:#2F92EE;'>#腋窝淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85323, encryptionId=7a6b8532324, topicName=腋窝淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Fri Oct 14 16:24:17 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729751, encodeId=4e721e2975127, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 03:24:17 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678764, encodeId=8b7716e87646c, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sun Jun 04 05:24:17 CST 2023, time=2023-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645991, encodeId=a24e16459910e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Tue Apr 04 20:24:17 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293181, encodeId=ffa81293181c8, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Aug 24 10:24:17 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240506, encodeId=93ac12405066f, content=现阶段,新辅助化疗(NAC)后进行手术治疗是局部晚期乳腺癌和淋巴结阳性患者的标准治疗手段。根据目前的指南,腋窝淋巴结清扫术(ALND)适用于在NAC之前有病理证实的淋巴结受累患者。然而,ALND可能导致如手臂疼痛、淋巴水肿和手臂活动受限等术后并发症。 因此,随着NAC效用的增加和化疗疗效的提高,对于NAC后转为淋巴结阴性的乳腺癌患者,ALND术式的使用受到了临床上的广泛质疑。对于这些患者,如前哨淋巴结活检(SLNB)等有针对性的腋窝清扫是现阶段普遍公认的ALND替代方法。 尽管越来越多的证据支持在最初淋巴结阳性的乳腺癌患者中进行SLNB的可行性,但假阴性率(FNRs)通常高得令人无法接受。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:05:27 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240505, encodeId=d26d124050559, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:04:33 CST 2022, time=2022-08-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1931877, encodeId=618c19318e775, content=<a href='/topic/show?id=7a6b8532324' target=_blank style='color:#2F92EE;'>#腋窝淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85323, encryptionId=7a6b8532324, topicName=腋窝淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Fri Oct 14 16:24:17 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729751, encodeId=4e721e2975127, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 03:24:17 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678764, encodeId=8b7716e87646c, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sun Jun 04 05:24:17 CST 2023, time=2023-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645991, encodeId=a24e16459910e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Tue Apr 04 20:24:17 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293181, encodeId=ffa81293181c8, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Aug 24 10:24:17 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240506, encodeId=93ac12405066f, content=现阶段,新辅助化疗(NAC)后进行手术治疗是局部晚期乳腺癌和淋巴结阳性患者的标准治疗手段。根据目前的指南,腋窝淋巴结清扫术(ALND)适用于在NAC之前有病理证实的淋巴结受累患者。然而,ALND可能导致如手臂疼痛、淋巴水肿和手臂活动受限等术后并发症。 因此,随着NAC效用的增加和化疗疗效的提高,对于NAC后转为淋巴结阴性的乳腺癌患者,ALND术式的使用受到了临床上的广泛质疑。对于这些患者,如前哨淋巴结活检(SLNB)等有针对性的腋窝清扫是现阶段普遍公认的ALND替代方法。 尽管越来越多的证据支持在最初淋巴结阳性的乳腺癌患者中进行SLNB的可行性,但假阴性率(FNRs)通常高得令人无法接受。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:05:27 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240505, encodeId=d26d124050559, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:04:33 CST 2022, time=2022-08-23, status=1, ipAttribution=)]
    2023-03-18 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1931877, encodeId=618c19318e775, content=<a href='/topic/show?id=7a6b8532324' target=_blank style='color:#2F92EE;'>#腋窝淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85323, encryptionId=7a6b8532324, topicName=腋窝淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Fri Oct 14 16:24:17 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729751, encodeId=4e721e2975127, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 03:24:17 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678764, encodeId=8b7716e87646c, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sun Jun 04 05:24:17 CST 2023, time=2023-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645991, encodeId=a24e16459910e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Tue Apr 04 20:24:17 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293181, encodeId=ffa81293181c8, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Aug 24 10:24:17 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240506, encodeId=93ac12405066f, content=现阶段,新辅助化疗(NAC)后进行手术治疗是局部晚期乳腺癌和淋巴结阳性患者的标准治疗手段。根据目前的指南,腋窝淋巴结清扫术(ALND)适用于在NAC之前有病理证实的淋巴结受累患者。然而,ALND可能导致如手臂疼痛、淋巴水肿和手臂活动受限等术后并发症。 因此,随着NAC效用的增加和化疗疗效的提高,对于NAC后转为淋巴结阴性的乳腺癌患者,ALND术式的使用受到了临床上的广泛质疑。对于这些患者,如前哨淋巴结活检(SLNB)等有针对性的腋窝清扫是现阶段普遍公认的ALND替代方法。 尽管越来越多的证据支持在最初淋巴结阳性的乳腺癌患者中进行SLNB的可行性,但假阴性率(FNRs)通常高得令人无法接受。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:05:27 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240505, encodeId=d26d124050559, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:04:33 CST 2022, time=2022-08-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1931877, encodeId=618c19318e775, content=<a href='/topic/show?id=7a6b8532324' target=_blank style='color:#2F92EE;'>#腋窝淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85323, encryptionId=7a6b8532324, topicName=腋窝淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Fri Oct 14 16:24:17 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729751, encodeId=4e721e2975127, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 03:24:17 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678764, encodeId=8b7716e87646c, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sun Jun 04 05:24:17 CST 2023, time=2023-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645991, encodeId=a24e16459910e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Tue Apr 04 20:24:17 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293181, encodeId=ffa81293181c8, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Aug 24 10:24:17 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240506, encodeId=93ac12405066f, content=现阶段,新辅助化疗(NAC)后进行手术治疗是局部晚期乳腺癌和淋巴结阳性患者的标准治疗手段。根据目前的指南,腋窝淋巴结清扫术(ALND)适用于在NAC之前有病理证实的淋巴结受累患者。然而,ALND可能导致如手臂疼痛、淋巴水肿和手臂活动受限等术后并发症。 因此,随着NAC效用的增加和化疗疗效的提高,对于NAC后转为淋巴结阴性的乳腺癌患者,ALND术式的使用受到了临床上的广泛质疑。对于这些患者,如前哨淋巴结活检(SLNB)等有针对性的腋窝清扫是现阶段普遍公认的ALND替代方法。 尽管越来越多的证据支持在最初淋巴结阳性的乳腺癌患者中进行SLNB的可行性,但假阴性率(FNRs)通常高得令人无法接受。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:05:27 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240505, encodeId=d26d124050559, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:04:33 CST 2022, time=2022-08-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1931877, encodeId=618c19318e775, content=<a href='/topic/show?id=7a6b8532324' target=_blank style='color:#2F92EE;'>#腋窝淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85323, encryptionId=7a6b8532324, topicName=腋窝淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Fri Oct 14 16:24:17 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729751, encodeId=4e721e2975127, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 03:24:17 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678764, encodeId=8b7716e87646c, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sun Jun 04 05:24:17 CST 2023, time=2023-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645991, encodeId=a24e16459910e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Tue Apr 04 20:24:17 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293181, encodeId=ffa81293181c8, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Aug 24 10:24:17 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240506, encodeId=93ac12405066f, content=现阶段,新辅助化疗(NAC)后进行手术治疗是局部晚期乳腺癌和淋巴结阳性患者的标准治疗手段。根据目前的指南,腋窝淋巴结清扫术(ALND)适用于在NAC之前有病理证实的淋巴结受累患者。然而,ALND可能导致如手臂疼痛、淋巴水肿和手臂活动受限等术后并发症。 因此,随着NAC效用的增加和化疗疗效的提高,对于NAC后转为淋巴结阴性的乳腺癌患者,ALND术式的使用受到了临床上的广泛质疑。对于这些患者,如前哨淋巴结活检(SLNB)等有针对性的腋窝清扫是现阶段普遍公认的ALND替代方法。 尽管越来越多的证据支持在最初淋巴结阳性的乳腺癌患者中进行SLNB的可行性,但假阴性率(FNRs)通常高得令人无法接受。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:05:27 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240505, encodeId=d26d124050559, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:04:33 CST 2022, time=2022-08-23, status=1, ipAttribution=)]
    2022-08-24 sodoo
  6. [GetPortalCommentsPageByObjectIdResponse(id=1931877, encodeId=618c19318e775, content=<a href='/topic/show?id=7a6b8532324' target=_blank style='color:#2F92EE;'>#腋窝淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85323, encryptionId=7a6b8532324, topicName=腋窝淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Fri Oct 14 16:24:17 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729751, encodeId=4e721e2975127, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 03:24:17 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678764, encodeId=8b7716e87646c, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sun Jun 04 05:24:17 CST 2023, time=2023-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645991, encodeId=a24e16459910e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Tue Apr 04 20:24:17 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293181, encodeId=ffa81293181c8, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Aug 24 10:24:17 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240506, encodeId=93ac12405066f, content=现阶段,新辅助化疗(NAC)后进行手术治疗是局部晚期乳腺癌和淋巴结阳性患者的标准治疗手段。根据目前的指南,腋窝淋巴结清扫术(ALND)适用于在NAC之前有病理证实的淋巴结受累患者。然而,ALND可能导致如手臂疼痛、淋巴水肿和手臂活动受限等术后并发症。 因此,随着NAC效用的增加和化疗疗效的提高,对于NAC后转为淋巴结阴性的乳腺癌患者,ALND术式的使用受到了临床上的广泛质疑。对于这些患者,如前哨淋巴结活检(SLNB)等有针对性的腋窝清扫是现阶段普遍公认的ALND替代方法。 尽管越来越多的证据支持在最初淋巴结阳性的乳腺癌患者中进行SLNB的可行性,但假阴性率(FNRs)通常高得令人无法接受。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:05:27 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240505, encodeId=d26d124050559, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:04:33 CST 2022, time=2022-08-23, status=1, ipAttribution=)]
    2022-08-23 yangchou

    现阶段,新辅助化疗(NAC)后进行手术治疗是局部晚期乳腺癌和淋巴结阳性患者的标准治疗手段。根据目前的指南,腋窝淋巴结清扫术(ALND)适用于在NAC之前有病理证实的淋巴结受累患者。然而,ALND可能导致如手臂疼痛、淋巴水肿和手臂活动受限等术后并发症。 因此,随着NAC效用的增加和化疗疗效的提高,对于NAC后转为淋巴结阴性的乳腺癌患者,ALND术式的使用受到了临床上的广泛质疑。对于这些患者,如前哨淋巴结活检(SLNB)等有针对性的腋窝清扫是现阶段普遍公认的ALND替代方法。 尽管越来越多的证据支持在最初淋巴结阳性的乳腺癌患者中进行SLNB的可行性,但假阴性率(FNRs)通常高得令人无法接受。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1931877, encodeId=618c19318e775, content=<a href='/topic/show?id=7a6b8532324' target=_blank style='color:#2F92EE;'>#腋窝淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85323, encryptionId=7a6b8532324, topicName=腋窝淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Fri Oct 14 16:24:17 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729751, encodeId=4e721e2975127, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 18 03:24:17 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678764, encodeId=8b7716e87646c, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sun Jun 04 05:24:17 CST 2023, time=2023-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645991, encodeId=a24e16459910e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Tue Apr 04 20:24:17 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293181, encodeId=ffa81293181c8, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Aug 24 10:24:17 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240506, encodeId=93ac12405066f, content=现阶段,新辅助化疗(NAC)后进行手术治疗是局部晚期乳腺癌和淋巴结阳性患者的标准治疗手段。根据目前的指南,腋窝淋巴结清扫术(ALND)适用于在NAC之前有病理证实的淋巴结受累患者。然而,ALND可能导致如手臂疼痛、淋巴水肿和手臂活动受限等术后并发症。 因此,随着NAC效用的增加和化疗疗效的提高,对于NAC后转为淋巴结阴性的乳腺癌患者,ALND术式的使用受到了临床上的广泛质疑。对于这些患者,如前哨淋巴结活检(SLNB)等有针对性的腋窝清扫是现阶段普遍公认的ALND替代方法。 尽管越来越多的证据支持在最初淋巴结阳性的乳腺癌患者中进行SLNB的可行性,但假阴性率(FNRs)通常高得令人无法接受。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:05:27 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240505, encodeId=d26d124050559, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Aug 23 12:04:33 CST 2022, time=2022-08-23, status=1, ipAttribution=)]
    2022-08-23 yangchou

    好文章,谢谢分享。

    0

相关资讯

Radiology:人工智能评估在乳腺癌钼靶筛查中的价值

研究表明,人工智能(AI)在乳腺钼靶检查中检测乳腺癌方面显示出十分有价值的结果。

European Radiology:在接受NAC的乳腺癌患者中,测量这一影像学指标可预测化疗相关脂肪性肝炎!

对于接受心脏毒性化疗药物(如蒽环类、环磷酰胺和曲妥珠单抗)的BC患者来说,其心血管疾病(CVD)的发病率明显增加。

150万年轻女性队列研究:避孕药升高癌症风险到停药后10年仍持续!?其中这类避孕药最应小心......

Lancet Reg Health Eur:瑞典15-34岁女性的激素避孕与乳腺癌和原位乳腺癌风险:一项基于注册的全国性研究

2022年浙江省家族遗传性肿瘤论坛

2022湘湖论坛,欢迎莅临

近30年中国乳腺癌「成绩单」重磅出炉!与日韩比孰优?到2034年又将如何?

BMC Cancer:1990年至2019年中国乳腺癌的负担、趋势和危险因素及其到2034年的预测:与日本和韩国的最新概述和比较

王涛教授:HER2阳性晚期乳腺癌治疗进展

我们一起跟随解放军总医院肿瘤医学部王涛教授对HER2阳性晚期乳腺癌治疗相关进展的文献回顾。